Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients
What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.
Breast Cancer
PFS, Progression free survival, 6 weeks
OS, Overall survival, From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 6 weeks
Fulvestrant sensitivity, Time cutoff of Fulvestrant PFS related to next line ET or CT efficacy, 6 weeks
There is no evidence of treatment after progression of Ful. We retrospectively evaluated HR+, HER2- MBC patients failed on Ful 500mg as first line or second line therapy from 2014 to 2017 in 6 institutions. Treatment pattern, PFS, OS and safety were analyzed to figure out the situation and efficacy of treatment after Fulvestrant.